Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | PGR | P06401 | 3/20 | 0.70 |
| ▸ | SHBG | P04278 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141359 | 0.96 | HIF1A (0.69) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL141850 | 0.94 | HIF1A (0.70) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL3488308 | 0.94 | HIF1A (0.70) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL23803941 | 0.92 | HIF1A (0.60) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL146929 | 0.91 | HIF1A (0.70) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL142560 | 0.90 | HIF1A (0.66) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL28637413 | 0.90 | HIF1A (0.70) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| Hydrocortisone SCHEMBL27558807 | 0.86 | HIF1A (0.81) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| SCHEMBL122186 | 0.85 | NR3C2 (0.79) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 | |
| Hydrocortisone SCHEMBL365193 | 0.85 | HIF1A (0.83) | HIF1AHSD17B10SMN1; SMN2NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112584874-A | Compositions and methods for treating leber's hereditary optic neuropathy | 武汉纽福斯生物科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230174939-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | STELLULAR BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-116024266-A | Compositions and methods for treating leber's hereditary optic neuropathy due to ND4 mutations | 武汉纽福斯生物科技有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4149497-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Platelet Biogenesis, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-1040829-A2 | Prokinetic agents for treating gastric hypomotility and related disorders | PFIZER INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-0979085-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-02-16 | — | — | EP | disclosed |
| US-5837713-A | Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-11-17 | — | — | US | disclosed |
| WO-1998037896-A1 | TREATMENT OF EOSINOPHIL-ASSOCIATED PATHOLOGIES, SUCH AS BRONCHIAL ASTHMA, WITH SYNERGISTIC COMBINATIONS OF GLUCOCORTICOIDS AND A LOCAL ANESTHETICS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5622993-A | CONSISTS OF WAX, OIL, WATER, A SURFACTANT AND LIDOCAINE HYDROCHLORIDE WHICH IS PARTIALLY DISSOVED IN WATER DROPLETS DISPERSED IN WAX | MEDICAL POLYMERS (US) | 1997-04-22 | — | — | US | disclosed |
| US-5597849-A | STEROIDS, ANTIBIOTICS, FUNGICIDES, ANTIHISTAMINES, ANTIINFLAMMATORIES, ANESTHETICS | MEDICAL POLYMER TECHNOLOGIES, INC. (US) | 1997-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | HIF1A 4622/4885HSD17B10 301/4885SMN1; SMN2 181/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | HIF1A 1602/4885HSD17B10 2384/4885SMN1; SMN2 1541/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | HIF1A 404/4885HSD17B10 1100/4885SMN1; SMN2 96/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HIF1A 1602/4885HSD17B10 2384/4885SMN1; SMN2 1541/4885 |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | HIF1A 4622/4885HSD17B10 301/4885SMN1; SMN2 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.